test paper - glevo range ,eye & ear drops- a

8/13/2019 TEST PAPER - Glevo Range ,Eye & Ear Drops- A

1/6

Division : Majesta TEST PAPER - Glevo Range, Eye & Ear Drops

Marks 5 Ti!e " !ins

-------------------------------------------------------------------------------------------------#$%$ Tik t'e rig't ans(er )Ea' arry one !ark*

1. Levofloxacin belongs to which of the following

a) 1st Generation Quinolones b) 2nd Generation Quinolones *"r+ Generation #inolones d) 4th Generation Quinolones

2. Mode of action of Glevo is by

a) nhibiting !ell wall synthesis. b) nhibiting "rotein synthesis

* n'i.iting D/A repliation d) nhibiting !ell #er$eability

%. &hat is the M! 'rea( "oint of Levofloxacin for susce#tible $icroorganis$s

a* 0 1 2g3!lb) 4 *g+$lc) , - *g+$ld) one of the above

4. &hat is the /ill 0atio of Levofloxacin

a) 4b) 43c) 4+* 4

. &hich of the following is not an indication for Levofloxacin

G6E/MAR7 P8ARMA9ET9A6S 6TD$


2/6

a* Ate Ma;illary Sinsitis in 9'il+renb) !o$$unity 5c6uired "neu$oniac) osoco$ial "neu$oniad) 5cute 7xacerbation of !hronic 'ronchitis

8. &hat is the usual strength of Levofloxacin used in M90 :'

a) 2; $g


3/6

1. Glevo is the first 6uinolone to be a##roved for the treat$ent of 5cute sinusitisdue

to greater activity against Streptoos pne!onae. MoreoverB is also thefirst S>DA

a##roved 6uinolone for "enicillin 0esistant =tre#tococcus "neu$onae C"0=").

2. 9osage of Glevo?3; in M90 ?:' CMention in detail ) Glevo-enceB Glevo is a su#erior choice to /or@lo;ain and 9ipro@lo;ainin!o$#licated and

Fnco$#licated F:.

. &hat are the indications of Glevo 7ye @ 7ar 9ro#s

=titis E;terna

Ate =titis Me+ia

9'roni Spprative =titis Me+ia )9S=M* aterial onjntivitis

1;. !oncentration of Levofloxacin in hu$an tears re$ains above the M!sC2$cg+$l) even after 4-Chrs.


4/6

#$" State ('et'er t'e state!ent is Tre or >alse

1. Glevo ?3; is reco$$ended in M90?:' by 5$erican :horacic 5ssociationB

nfectious 9isease =ociety of 5$ericaB and !enter for 9isease !ontrol. C Tre)

2. 9osage of Glevo in !o$#licated F: 2; $g once daily 3 ? 1; days including "yelone#hritis. C Tre)

%. :reating one M90?:' #atients costs the sa$e as treating 1;; regular :'#atients. C Tre)

4. Glevo offers significant activity against soniaHid ? 0ifa$#icinB soniaHid?=tre#to$ycin and

alse)

8. Glevo has e6ual efficacy in =inusitisB "haryngitis and 'ronchitis as co$#ared to0oxithro$ycinB and !efadroxil C >alse)

3. F=D95 has a##roved Glevo 3; for 3 days in the treat$ent of !o$$unity5c6uired

"neu$onia C >alse)

-.Glevois 2?4 ti$es greater antibacterial activity than


5/6

#$4 Mat' t'e @ollo(ing :

5 '

1. 8;E >os#ital nfections are due to a. =u##ress #roinfla$$atory cyto(inesto

i$#rove i$$uno$odulatoryfunctionB

hence is the first 6uinolone to be

a##roved by F=D952. Mode of action of Levofloxacin b. lacta$ase #roducing

%. 56ueous solubility of Levofloxacin in7ye+7ar dro#s

c. a #erforated ty$#anic $e$branewith #ersistent drainage fro$ the

$iddleear

4. Glevo 3;


6/6

re#lication.

5nswers C1? @)BC2? l)BC%?j)BC4? ')BC? k)BC8? g )BC3? e)BC-? a)BC? )B C1;? . )BC11?i)BC12? +)

test paper - glevo range ,eye & ear drops- a

Documents